We compared the activity and physiologic effects of cardiac angiotensin converting enzyme (ACE) using isovolumic hearts from male Wistar rats with left ventricular hypertrophy due to chronic experimental aortic stenosis and from control rats. In response to the infusion of 3.5 X 10-8 M angiotensin I in the isolated buffer perfused beating hearts, the intracardiac fractional conversion to angiotensin II was higher in the hypertrophied hearts compared with the controls (17.3±4.1% vs 6.8±1.3%, P < 0.01). ACE activity was also significantly increased in the free wall, septum, and apex of the hypertrophied left ventricle, whereas ACE activity from the nonhypertrophied right ventricle of the aortic stenosis rats was not different from that of the control rats. Northern blot analyses of poly(A)+ purified RNA demonstrated the expression of ACE mRNA, which was increased fourfold in left ventricular tissue obtained from the hearts with left ventricular hypertrophy compared with the controls. In both groups, the intracardiac conversion of angiotensin I to angiotensin II caused a comparable dose-dependent increase in coronary resistance. In the control hearts, angiotensin II activation had no significant effect on systolic or diastolic function; however, it was associated with a dose-dependent depression of left ventricular diastolic relaxation in the hypertrophied hearts. These novel observations suggest that cardiac ACE is induced in hearts with left ventricular hypertrophy, and that the resultant intracardiac activation of angiotensin II may have differential effects on myocardial relaxation in hypertrophied hearts relative to controls. (J. Clin.
Introduction
There is increasing recognition of the existence of an endogenous renin-angiotensin system in the heart. Evidence supporting the presence of this system in cardiac tissue includes the demonstration of angiotensinogen and renin mRNAs (1) (2) (3) (4) , and the biochemical identification of renin, angiotensin converting enzyme (ACE),' and angiotensin II, as well as its receptor, in the heart (5) (6) (7) (8) (9) . Furthermore, the intracardiac activation of angiotensin I to angiotensin II has been demonstrated in isolated perfused hearts (10) . The physiologic roles of this angiotensin Il-generating pathway have not been defined and may include local effects on cardiac contractility, coronary vasomotor tone, arrythmogenesis, as well as a permissive or regulatory role in modulating cardiac growth and development (5, 10) . There is indirect evidence that supports the role of the renin-angiotensin system in the initiation of protooncogene expression and cell growth in smooth muscle and myocardial cells (1 1-17) , and inhibition has been shown to prevent left ventricular hypertrophy in rats with pressure overload (18) (19) (20) , and promote the regression of chronic pressure overload hypertrophy in humans (21, 22) . The potential functional significance of the intracardiac conversion of angiotensin I to angiotensin II in the presence of chronic pressure overload hypertrophy is unknown. If angiotensin plays a regulatory role in the development of compensatory pressure overload hypertrophy, the activity of a physiological pathway for the conversion of angiotensin I to angiotensin II may be amplified in hearts with compensatory pressure overload hypertrophy. To test this hypothesis, we compared the conversion of angiotensin I to II and its physiologic effects on coronary vasoreactivity and systolic and diastolic function in isolated beating bufferperfused hearts from rats with chronic aortic stenosis and from age-matched controls. In addition, ACE activity and mRNA were measured in cardiac tissue obtained from the hypertrophied and control hearts. Our experiments demonstrated that cardiac ACE activity and mRNA were increased in the hypertrophied ventricle and that the increased rate of angiotensin II production was associated with altered diastolic properties in the hypertrophied hearts.
Methods
Preparation ofanimals. Male Wistar rats were obtained by the Charles River Breeding Laboratories (Wilmington, DE) . Aortic stenosis was created in weanling rats (body weight, 100 g; age, 3-4 wk) by placing a stainless steel clip of 0.6 mm internal diameter on the ascending aorta via a thoracic incision. Age-matched control animals underwent a left thoracotomy. The rats were subsequently fed normal rat chow (Purina) and water ad libitum, and were used for experimentation [8] [9] wk after operation. The body weight was recorded, and serum was obtained from the animals before they were killed.
Perfusion technique. The isolated isovolumic working rat heart preparation has previously been described in detail (23) . Rats were injected intraperitoneally with 1.0-1.5 ml sodium pentobarbital ( (25) to be required for accurate measurement ofleft ventricular pressure and its first derivative. To assess left ventricular chamber distensibility, left ventricular balloon volume was initially adjusted to 10 mmHg in both groups, and this balloon volume was held constant so that an increase in left ventricular end diastolic pressure (LVEDP) signified a decrease in diastolic chamber distensibility (23, 24) . Coronary perfusion pressure was measured from a sidearm of the aortic perfusion cannula connected to a Statham P23Db pressure transducer. The coronary flow rate was measured by timed samples of coronary venous effluent collected from the pulmonary artery cannula.
Experimental protocol: infusion of angiotensin I in the isolated perfused hearts. Before each experiment, the heart was perfused for a stabilization period of 20 min at a paced heart rate of 4 Hz which was continued throughout the experiment. In hearts from the rats with chronic aortic stenosis (LVH group, n = 9), coronary flow was adjusted to achieve a mean coronary perfusion pressure (CPP) of 100 mmHg and was then fixed at that level of flow throughout the subsequent experiment. In the control group (C, n = 12) coronary flow was adjusted to achieve a CPP of 80 mm Hg and was then fixed at that level throughout the experiment. These differing levels of coronary flow and initial coronary perfusion pressures were selected in recognition of the difference between the in vivo mean coronary perfusion pressures to which the control and LVH groups were chronically exposed, and because pilot studies showed that this approach would achieve comparable myocardial perfusion flow rates per gram of left ventricular weight and an aerobic pattern of myocardial lactate extraction (26) 7.4 with 1 mg/ml BSA), and RIA performed as previously described (27) . The sensitivity of this assay is 0.1-1.2 ng/tube. Since RIA was always performed after HPLC, the crossreactivity of the angiotensin II antibody with angiotensin III or nonangiotensin peptides was avoided. The fractional conversion rate was calculated as [(Ang II, M)/(Ang I + Ang II, M)] x 100.
Measurement ofserum and cardiac tissue ACE activity. Serum and cardiac ACE activity was measured by the rate of generation of HisLeu from Hip-His-Leu substrate using fluorometric assay described by Cushman and Cheung (28) . Tissue was homogenized in ice-cold 50 mM potassium phosphate buffer, pH 7.5. An aliquot of the homogenized samples was then incubated with 12.5 mM Hip-His-Leu for 10 min at 37°C in a shaking waterbath. The reaction was stopped by adding 280 mM NaOH. Blank controls were treated in the same fashion, with the exception that Hip-His-Leu was added after NaOH treatment. Phthalaldehyde 1% was then added to the aliquots for 10 (Fig. 1) .
Fractional conversion ofangiotensin I to II in the isolated perfused heart. Neither of the angiotensins was found in the coronary venous effluent when hearts were perfused with buffer solution alone. In response to perfusion with 3.5 X 10-8 M angiotensin I, the intracardiac conversion rate of angiotensin I to II in the perfused hearts was 17 (Table I) .
In response to the infusion of angiotensin I, there was a dose-related increase in coronary vascular resistance in both the LVH and the control group (P < 0.05 for both groups). The increase in coronary vascular resistance was similar for the LVH and control groups (Fig. 2) . There was no significant dose-related effect of angiotensin I infusion on left ventricular developed pressure in either the LVH or the control group ( Figure 3 ). There was also no significant dose-related effect of angiotensin I infusion on left ventricular +dP/dt in either group. Fig. 4 shows the dose-related effects of angiotensin I infusion on isovolumic LVEDP in both groups. At baseline, LVEDP was adjusted to a similar level of 10 mm Hg in the LVH and control groups (Table I) . In response to angiotensin I infusion, there was no change in isovolumic LVEDP in the control group. However, the LVH group showed a dose-related increase in LVEDP to a level of 17±2 mm Hg (P < 0.05), at a concentration of 3.5 X 1o-8 M, and to a level of 30±4 mm Hg (P = 0.05) at the higher concentration of 3.5 X l0-7 M. Left ventricular -dP/dt also decreased in the LVH group in comparison with the control group (P < 0.05). Measurement of cardiac ACE activity. We studied ACE activity in tissue obtained from three regions of the left ventricle (free wall, septum, and apex) and the right ventricle of the LVH and the control groups. As shown in Fig. 5 , in the LVH group, cardiac ACE activity was significantly increased in all three regions of the left ventricle. However, ACE activity was similar in the serum, and in right ventricular tissue from the LVH and the control groups it was similar (24 vs. 27 nm/ min/g, P = NS).
Measurement ofcardiac ACE mRNA. Northern blot analyses demonstrated ACE mRNA expression in the left ventricles of both groups (Fig. 6) . The electrophoretic migration of cardiac ACE mRNA was identical with rat pulmonary ACE mRNA. Rat testicular RNA, an additional control, contained a smaller ACE transcript, similar to that which has already been shown for human and mouse testicular ACE mRNA (30, 31) . In left ventricular tissue from the LVH group, cardiac ACE mRNA showed much stronger signals than in shamoperated controls ( bases), which was added to total RNA before poly(A)+ RNA purification and served as a recovery marker, was well separated from ACE mRNA. Using laser densitometry, we determined the ratios of the signal density for ACE mRNA and anglerfish-insulin mRNA. As shown in Fig. 7 , there was a fourfold increase in ACE mRNA in the left ventricular tissue from the LVH group as compared with the controls (P < 0.05).
Discussion
Recent observations indicate that endogenous renin-angiotensin systems are localized in multiple tissues, including the heart (1, 5, 32) . Biochemical studies have demonstrated the presence of renin and angiotensins (10, 33) , and ACE activity in cardiac tissue (28) . The presence of high affinity angiotensin II receptors have been demonstrated in the rat conduction system, cardiac endothelium and isolated myocytes (7, 9) , and in cardiac tissue from other species (6, 8, 34 (10) , who infused angiotensin I into isolated, buffer-perfused rat hearts and reported a fractional conversion of angiotensin I to II of 6.4% in normal adult rat hearts. Using a similar methodology our findings corroborate this fractional conversion in normal Figure 6 . Northern blot analysis of rat testicular and pulmonary ACE mRNA, and cardiac mRNA from left ventricular tissue obtained from the LVH and control groups. The blot was hybridized with an oligolabeled human ACE cDNA. Using 25 mg poly(A)+ RNA, all hearts gave a clear signal. This demonstrates the local expression of ACE mRNA in the rat heart. Furthermore, the signal from tissue of the LVH group hearts is increased relative to the controls. Anglerfish insulin mRNA (AF-I) served as a recovery marker.
hearts (6.7%). In the studies of Lindpaintner et al. (10, 36) , the ACE inhibitors captopril, ramiprilat, and cilaprilat each resulted in an immediate and dose-dependent reduction of angiotensin I to II conversion. In the present study, we used enalaprilat which decreased the intracardiac conversion rate of angiotensin I to II to 2.1%. However, tissue angiotensin II generation might be modulated by an endogenous inhibitor of ACE (37) or angiotensin II-generating enzymes other than ACE, as well (38, 39) . Our findings do not exclude the presence of additional angiotensin II-generating enzymes, since enalaprilat inhibited 70%, but not all, of the angiotensin I conversion in normal rat hearts. The present study was designed to study the role ofcardiac ACE in pressure overload hypertrophy. The fractional conversion of angiotensin I to II was significantly higher in hypertrophied hearts (17.3%) as compared with controls, and enalaprilat decreased this conversion rate to 2.9%. This observation was corroborated by biochemical measurements of ACE activity that showed significantly higher zp I -r-ACE activity in all three regions of the hypertrophied left ventricles relative to the control hearts. In contrast, the ACE activity from the right ventricles, which did not undergo hypertrophy, was not increased relative to that of right ventricular tissue from the control hearts. This shows that the stimulus for increased ACE expression is associated directly with the hypertrophic response to an increase in load, and is not a systemic or blood-borne factor. This is consistent with the finding of Hirsch et al. (40) ofa regional increase in tissue ACE activity in noninfarcted tissue that had undergone compensatory hypertrophy in rats after coronary ligation relative to sham-operated controls. Recent studies have demonstrated multiple sites of ACE localization, including the coronary vasculature, atrial and ventricular myocardium, and the valve leaflets in the rat heart (41), but we have not yet localized the primary sites of the intracardiac ACE in this aortic stenosis rat model. Induction ofcardiac ACE mRNA. In this study, we showed for the first time that ACE messenger RNA is locally expressed in the heart, and that its expression is induced more than fourfold in left ventricular tissue from hypertrophied hearts relative to controls. It remains to be established whether the enhanced expression ofACE is consistent with the reinduction of a fetal pattern of gene expression in chronic hypertrophy (42) . Increased angiotensin II synthesis may play a role in the initiation of cardiac hypertrophy. There is evidence that angiotensin II can stimulate protooncogene induction, protein synthesis, and cell growth in smooth muscle and myocardial cells (12-17, 43, 44) .
Our observation of increased expression of ACE mRNA in the hypertrophied left ventricles of rats with chronic aortic stenosis suggests that the cardiac angiotensin system may also contribute to the maintenance ofestablished pressure overload hypertrophy. This notion is supported by the observation that chronic converting enzyme inhibition caused regression of hypertrophy in the model of experimental aortic stenosis that we used in our study (18) , and by the preliminary finding that left ventricular angiotensinogen mRNA levels are several-fold higher in spontaneously hypertensive rats with chronic hypertrophy compared with nonhypertrophied controls (45) .
Physiologic effects of angiotensin II activation. Our study also showed that the intracardiac conversion of angiotensin I to II causes dynamic changes in cardiac physiology. The infusion of angiotensin I elicited a dose-related increase in coronary vascular tone in the isolated hearts that was of similar magnitude in the LVH and control groups. The finding that the relative change in coronary vascular resistance was similar in both groups in the presence of an increased conversion of angiotensin I to II in the hypertrophied hearts raises the possibility that the effect of angiotensin II on coronary vascular reactivity is blunted in the hypertrophied heart. In this regard, preliminary studies on angiotensin II receptor density and affinity in hypertrophied left ventricular tissue from rats with aortic stenosis demonstrated a lower receptor density and no change in affinity compared with sham-operated control hearts (Tang, S. S., personal communication). Alternatively, the site of increased production of angiotensin II in the hypertrophied heart may be at the level of the myocyte rather than the vasculature.
Heart rate was controlled by pacing, and we did not study the chronotropic effects of angiotensin II. Angiotensin II activation did not elicit a statistically significant dose-dependent positive inotropic effect in either the LVH or the control group. Conflicting observations of the inotropic effects of angiotensin II may be related to experimental differences in the confounding factor of angiotensin-induced sympathetic neurotransmitter release (46) , and variation between species. Positive inotropic effects, independent of the ,3-adrenergic system and cyclic AMP activation, have been reported for the rabbit, cat, dog, and hamster (6, 39, (47) (48) (49) (50) . In contrast, no response or a negative inotropic response has been reported for the rat and guinea pig (10, 34, 51) over a concentration range of angiotensin II similar to that obtained by the fractional conversion of angiotensin I in our study.
The direct myocardial effects of angiotensin II activation on diastolic relaxation have received little attention. In this study, angiotensin II activation had no effects on isovolumic left ventricular diastolic pressure in the control group. In contrast, angiotensin I infusion caused a significant dose-dependent increase in isovolumic left ventricular diastolic pressure in the LVH group consistent with a decrease in diastolic distensibility (23, 24) . In isovolumic buffer-perfused hearts, consideration must be given to the contribution ofcoronary turgor on changes in diastolic pressure (52) . However, in this experiment, changes in coronary turgor are unlikely to account for the deterioration of diastolic function in the LVH group since coronary flow was held constant and was similar in both groups at baseline and during angiotensin I infusion.
Our findings are consistent with recent observations of Allen et al. (51) using isolated beating rat myocytes who found that angiotensin II increased the "L-type" Ca2" current in the absence of any effect on adenylate cyclase, whereas both shortening and relaxation velocity decreased. These findings lend support to the notion that the effects of angiotensin in our isolated rat heart model were direct rather than being mediated by sympathetic neurotransmitter release (46) . Instead, the effects of angiotensin II on cardiac performance (34, 51, 53, 54) and on growth (16, 17) appear to be associated with the activation of phosphoinositide second messengers (55-57) and changes in the mobilization and reuptake of cytosolic [Ca2+]i. Cardiac [Ca2+]i homeostasis, which is a major determinant of diastolic function, is profoundly altered in hypertrophied rat myocytes (57) (58) (59) , and there is evidence that IP3-induced sarcoplasmic reticulum Ca2' release is enhanced (60) . We postulate that the deterioration of diastolic function induced by angiotensin II activation that we observed may be related to the effects of phosphoinositide second messengers on the slowed [Ca2+]i reuptake which is characteristic of hypertrophied myocytes.
Additional studies will need to be done to determine if our findings are relevant to pressure-overload in other species and in humans with chronic cardiac hypertrophy. In this regard, Foult et al. have shown that the intracoronary infusion of the ACE inhibitor enalaprilat in patients with increased left ventricular mass and dilated cardiomyopathy causes a fall in coronary vascular resistance, a slight depression of indices of systolic pump function, and a reduction in elevated left ventricular diastolic pressure without change in end-diastolic volume (61) . These data are consistent with the hypothesis that the intracardiac activation of angiotensin II is present in humans, and may contribute to abnormal diastolic function and development of congestive heart failure in patients with chronic hypertrophy from aortic stenosis and hypertension.
